MAIA Biotechnology, Inc. announced that independent directors purchased common stock and warrants in a recent private placement offering, totaling approximately $1.51 million. Directors and officers now hold 13.43% of MAIA, reflecting strong confidence in ateganosine, an anticancer treatment for NSCLC. The FDA granted Fast Track designation for ateganosine, pointing to a high probability of regulatory approval. Ateganosine is an investigational telomere-targeting agent showing promise in cancer treatment, inducing selective cancer cell death. MAIA focuses on developing first-in-class drugs to improve cancer patient outcomes. For more information, visit www.maiabiotech.com.

Read more at GlobeNewswire: MAIA Biotechnology Board Members Continue to Participate in